NASDAQ:AVRO AVROBIO - AVRO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AVROBIO, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.93 -0.01 (-1.06%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.90▼$0.9650-Day Range$0.69▼$0.9452-Week Range$0.56▼$1.90Volume362,588 shsAverage Volume284,247 shsMarket Capitalization$40.71 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media AVROBIO MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside330.1% Upside$4.00 Price TargetShort InterestHealthy0.36% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.18) to ($1.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.87 out of 5 starsMedical Sector604th out of 1,029 stocksBiological Products, Except Diagnostic Industry95th out of 169 stocks 3.5 Analyst's Opinion Consensus RatingAVROBIO has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, AVROBIO has a forecasted upside of 330.1% from its current price of $0.93.Amount of Analyst CoverageAVROBIO has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.36% of the float of AVROBIO has been sold short.Short Interest Ratio / Days to CoverAVROBIO has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AVROBIO has recently increased by 2.32%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAVROBIO does not currently pay a dividend.Dividend GrowthAVROBIO does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVRO. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 3 people have searched for AVRO on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added AVROBIO to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AVROBIO insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of AVROBIO is held by insiders.Percentage Held by Institutions55.74% of the stock of AVROBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for AVROBIO are expected to grow in the coming year, from ($2.18) to ($1.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AVROBIO is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AVROBIO is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAVROBIO has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AVROBIO (NASDAQ:AVRO) StockAvrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.Read More Receive AVRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address AVRO Stock News HeadlinesDecember 7, 2022 | finance.yahoo.comAVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene TherapyNovember 17, 2022 | finance.yahoo.comAVROBIO to Share Comprehensive Gaucher Disease Program UpdateFebruary 4, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! November 8, 2022 | finance.yahoo.comAVROBIO Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 7, 2022 | finance.yahoo.comAVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy SummitOctober 27, 2022 | finance.yahoo.comAVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher DiseaseOctober 25, 2022 | finance.yahoo.comAVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for CystinosisOctober 18, 2022 | seekingalpha.comAvrobio stock rises as gene therapy for Gaucher disease gets ILAP designation in UK - Seeking AlphaFebruary 4, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! October 18, 2022 | businesswire.comAVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease - Business WireOctober 18, 2022 | finance.yahoo.comAVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher DiseaseOctober 11, 2022 | businesswire.comAVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development - Business WireOctober 11, 2022 | finance.yahoo.comAVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical DevelopmentOctober 8, 2022 | businesswire.comAVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - businesswire.comSeptember 27, 2022 | businesswire.comAVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress - Business WireSeptember 27, 2022 | finance.yahoo.comAVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual CongressSeptember 20, 2022 | benzinga.comAVROBIO Receives Rare Pediatric Disease Designation From FDA For First Gene Therapy In Development For Cy - BenzingaSeptember 20, 2022 | businesswire.comAVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis - Business WireSeptember 20, 2022 | finance.yahoo.comAVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for CystinosisSeptember 14, 2022 | businesswire.comAVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial - Business WireSeptember 14, 2022 | finance.yahoo.comAVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy TrialAugust 31, 2022 | businesswire.comAVROBIO to Participate in Four Upcoming Investor Conferences in September - Business WireAugust 31, 2022 | finance.yahoo.comAVROBIO to Participate in Four Upcoming Investor Conferences in SeptemberAugust 29, 2022 | reuters.comAVRO.O - Avrobio Inc | Stock Price & Latest News | ReutersAugust 28, 2022 | fool.comAvrobio, Inc. (NASDAQ: AVRO)August 17, 2022 | businesswire.comSonoma Biotherapeutics Expands Board of Directors with Appointments of Katina Dorton, J.D., MBA, and John Davis, M.D., MPH - Business WireAugust 17, 2022 | finance.yahoo.comGlobal Gaucher Disease Treatment Market to Grow at ~5% CAGR during 2022-2031; Market to Expand Owing to Worldwide Prevalence of Gaucher Disease, Rapid R&D Progress, and Government Actions for Therapeutic Advances– Kenneth Research - Yahoo FinanceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AVRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address AVRO Company Calendar Last Earnings11/08/2022Today2/04/2023Next Earnings (Estimated)3/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVRO CUSIPN/A CIK1681087 Webwww.avrobio.com Phone(617) 914-8420FaxN/AEmployees122Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$4.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+330.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,130,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-82.47% Return on Assets-66.62% Debt Debt-to-Equity Ratio0.16 Current Ratio7.80 Quick Ratio7.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.88 per share Price / Book0.24Miscellaneous Outstanding Shares43,770,000Free Float40,972,000Market Cap$40.71 million OptionableNot Optionable Beta1.76 Key ExecutivesGeoff MacKayPresident, Chief Executive Officer & DirectorErik John OstrowskiChief Financial Officer & TreasurerKim RaineriChief Manufacturing & Technical Operations OfficerEssra RidhaChief Medical OfficerDeanna M. PetersenChief Business OfficerKey CompetitorsEvaxion Biotech A/SNASDAQ:EVAXERYTECH PharmaNASDAQ:ERYPTScan TherapeuticsNASDAQ:TCRXFreeline TherapeuticsNASDAQ:FRLNProtara TherapeuticsNASDAQ:TARAView All CompetitorsInsiders & InstitutionsGMT Capital CorpSold 184,631 shares on 2/3/2023Ownership: 7.562%Vanguard Group Inc.Bought 136,827 shares on 11/15/2022Ownership: 2.644%Citadel Advisors LLCSold 202,498 shares on 11/15/2022Ownership: 1.170%Two Sigma Investments LPSold 81,020 shares on 11/15/2022Ownership: 0.897%Two Sigma Advisers LPSold 175,800 shares on 11/15/2022Ownership: 0.896%View All Institutional Transactions AVRO Stock - Frequently Asked Questions Should I buy or sell AVROBIO stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AVRO shares. View AVRO analyst ratings or view top-rated stocks. What is AVROBIO's stock price forecast for 2023? 1 equities research analysts have issued 1 year target prices for AVROBIO's shares. Their AVRO share price forecasts range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 330.1% from the stock's current price. View analysts price targets for AVRO or view top-rated stocks among Wall Street analysts. How have AVRO shares performed in 2023? AVROBIO's stock was trading at $0.7129 at the start of the year. Since then, AVRO stock has increased by 30.5% and is now trading at $0.93. View the best growth stocks for 2023 here. When is AVROBIO's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023. View our AVRO earnings forecast. How were AVROBIO's earnings last quarter? AVROBIO, Inc. (NASDAQ:AVRO) announced its quarterly earnings data on Tuesday, November, 8th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.02. What other stocks do shareholders of AVROBIO own? Based on aggregate information from My MarketBeat watchlists, some companies that other AVROBIO investors own include Sorrento Therapeutics (SRNE), ImmunoGen (imgn), Aduro Biotech (ADRO), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Biohaven (BHVN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB), VBI Vaccines (vbiv) and Arbutus Biopharma (ABUS). When did AVROBIO IPO? (AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager. What is AVROBIO's stock symbol? AVROBIO trades on the NASDAQ under the ticker symbol "AVRO." Who are AVROBIO's major shareholders? AVROBIO's stock is owned by a number of retail and institutional investors. Top institutional investors include GMT Capital Corp (7.56%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Christopher Paige, Geoffrey Mackay and Philip J Vickers. View institutional ownership trends. How do I buy shares of AVROBIO? Shares of AVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AVROBIO's stock price today? One share of AVRO stock can currently be purchased for approximately $0.93. How much money does AVROBIO make? AVROBIO (NASDAQ:AVRO) has a market capitalization of $40.71 million. The company earns $-119,130,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. How many employees does AVROBIO have? The company employs 122 workers across the globe. How can I contact AVROBIO? AVROBIO's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The official website for the company is www.avrobio.com. The company can be reached via phone at (617) 914-8420 or via email at ir@ampliphibio.com. This page (NASDAQ:AVRO) was last updated on 2/4/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.